Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $475000.0.

  • Ironwood Pharmaceuticals' Depreciation & Amortization (CF) fell 631.16% to $475000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 647.69%. This contributed to the annual value of $1.2 million for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Depreciation & Amortization (CF) stood at $475000.0, which was down 631.16% from $467000.0 recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Depreciation & Amortization (CF) peaked at $513000.0 during Q1 2024, and registered a low of $270000.0 during Q2 2023.
  • Its 5-year average for Depreciation & Amortization (CF) is $418315.8, with a median of $410000.0 in 2021.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Depreciation & Amortization (CF) tumbled by 8034.05% in 2021, and later surged by 8740.74% in 2024.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Depreciation & Amortization (CF) stood at $359000.0 in 2021, then dropped by 5.29% to $340000.0 in 2022, then soared by 50.59% to $512000.0 in 2023, then fell by 5.27% to $485000.0 in 2024, then decreased by 2.06% to $475000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $475000.0 in Q3 2025, compared to $467000.0 in Q2 2025 and $479000.0 in Q1 2025.